The Role of Cetuximab in the Treatment of Metastatic Colorectal Cancer

被引：0
作者：
Holubec, Lubos [1 ]
Liska, Vaclav [2 ]
Matejka, Vit M. [1 ]
Fiala, Ondrej [1 ]
Dreslerova, Jana [1 ]
Mrazkova, Petra [3 ,4 ]
Treska, Vladislav [2 ]
Finek, Jindrich [1 ]
机构：
[1] Charles Univ Prague, Dept Oncol & Radiotherapy, Sch Med, Prague, Czech Republic
[2] Charles Univ Prague, Dept Surg, Sch Med, Prague, Czech Republic
[3] Charles Univ Prague, Dept Radiol, Sch Med, Prague, Czech Republic
[4] Charles Univ Prague, Teaching Hosp Pilsen, Prague, Czech Republic
来源：
ANTICANCER RESEARCH | 2012年 / 32卷 / 09期
关键词：
KRAS; cetuximab; colorectal cancer; liver metastases; review; PLUS IRINOTECAN; 1ST-LINE TREATMENT; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; LIVER METASTASES; OXALIPLATIN; FLUOROPYRIMIDINE; LEUCOVORIN; RESECTION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted biological therapy is becoming a standard in personalized medicine for patients with advanced stages of cancer. Treatment with cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, represents an example of personalized anticancer the for patients with metastatic colorectal cancer and wild (non-mutated) type of the Kirsten rat sarcoma viral oncogene (KRAS). Here the role of cetuximab in treating metastatic colorectal cancer is discussed with a focus on the treatment of hepatic metastases.
引用
收藏
页码：4007 / 4011
页数：5
相关论文
共 50 条
  • [21] RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
    Wu, Bin
    Yao, Yuan
    Zhang, Ke
    Ma, Xuezhen
    ONCOTARGET, 2017, 8 (41) : 71164 - 71172
  • [22] Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study
    Feliu Batlle, J.
    Cuadrado, E.
    Castro, J.
    Caldes, T.
    Belda, C.
    Sastre, J.
    Barriuso, J.
    Martinez Marin, V.
    Diaz-Rubio, E.
    Gonzalez-Baron, M.
    CHEMOTHERAPY, 2011, 57 (02) : 138 - 144
  • [23] Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese patients
    Chen, M. C.
    Chiang, F. F.
    Wang, H. M.
    NEOPLASMA, 2013, 60 (05) : 561 - 567
  • [24] A Japanese Post-marketing Surveillance of Cetuximab (Erbitux) in Patients with Metastatic Colorectal Cancer
    Ishiguro, Megumi
    Watanabe, Toshiaki
    Yamaguchi, Kensei
    Satoh, Taroh
    Ito, Hideyuki
    Seriu, Taku
    Sakata, Yuh
    Sugihara, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (04) : 287 - 294
  • [25] Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland
    Chapman, Suzannah J.
    McKavanagh, Daniel
    Burge, Matthew E.
    McPherson, Ian
    Walpole, Euan
    Hollingworth, Samantha A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E253 - E261
  • [26] Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer
    Wen, Feng
    Li, Qiu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (23) : 5332 - 5341
  • [27] Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer
    Feng Wen
    Qiu Li
    World Journal of Gastroenterology, 2016, (23) : 5332 - 5341
  • [28] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Sato, Yasushi
    Hirakawa, Masahiro
    Ohnuma, Hiroyuki
    Takahashi, Minoru
    Okamoto, Tetsuro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Furuhata, Tomohisa
    Takemasa, Ichiro
    Kato, Junji
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1133 - 1139
  • [29] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [30] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    Abdelwahab, S.
    Azmy, A.
    Abdel-aziz, H.
    Salim, H.
    Mahmoud, A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (09) : 1487 - 1492
12345